A phase 2, randomized study of Velcade (bortezomib), dexamethasone, and thalidomide versus Velcade, dexamethasone, thalidomide, and cyclophosphamide in subjects with previously untreated multiple myeloma who are candidates for autologous transplantation.

Next Previous
Trial Profile

A phase 2, randomized study of Velcade (bortezomib), dexamethasone, and thalidomide versus Velcade, dexamethasone, thalidomide, and cyclophosphamide in subjects with previously untreated multiple myeloma who are candidates for autologous transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Bortezomib; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Millennium

    • Most Recent Events

    • 22 Oct 2012 Primary endpoint 'Near-complete-haematological-response-rate' has not been met.
    • 23 Jun 2012 Additional locations (Czech Republic, France, Hungary, Italy, Portugal) added as reported by European Clinical Trials Database record.
    • 13 Jun 2010 Results presented at the 15th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top